Earnings ·
Enovis Corporation reported financial results for the second quarter ended July 3, 2026, announcing net sales of $583…
ENOVEnovis Corp
Enovis Corporation reported financial results for the second quarter ended July 3, 2026, announcing net sales of $583 million, a 3% increase on a reported basis and 5% organic growth compared to the prior year. The company posted a net loss of $1 million, or $0.02 per diluted share, alongside adjusted EBITDA of $104 million, representing a 17.9% margin. Reconstructive sales grew 8% reported (6% organic), while Prevention & Recovery sales declined 1% reported but grew 3% organically. Enovis reaffirmed its full-year 2026 guidance, projecting revenue between $2.31 billion and $2.37 billion, adjusted EBITDA of $425 million to $435 million, and adjusted EPS of $3.52 to $3.73. The company operates in the medical technology industry, developing solutions for patient recovery and reconstructive surgery.